JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
After market 04:56:11 am | |||
| 154.6 USD | +0.23% |
|
155 | +0.26% |
| 17/05 | J&J-backed startup Rapport files for US IPO | RE |
| 17/05 | J&J-Linked Rapport Therapeutics Files For IPO | DJ |
Presenter SpeechUnknown Executive (Executives)Ladies and gentlemen, please welcome our Chairma...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
20/05/2024
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
154.6
USD
Average target price
173.3
USD
Spread / Average Target
+12.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.34% | 372B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson - Shareholder/Analyst Call
